1. Charman, Susan., McClenaghan, Elliot., Cosgriff, Rebecca., Lee, Andrew., Carr S. UK Cystic Fibrosis Registry Annual data report 2018, https://www.cysticfibrosis.org.uk/sites/default/files/2020-12/2018 (2019, accessed 11 May 2021).
2. Agent P, Parrott H. Inhaled therapy in cystic fibrosis: agents, devices and regimens. Breathe 2015; 11: 111–118.
3. Southern KW, Barker PM, Solis-Moya A, et al. Macrolide antibiotics for cystic fibrosis. In: Southern KW (ed) Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 2011. Epub ahead of print December 2011. DOI: 10.1002/14651858.CD002203.pub3.
4. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation. N Engl J Med 2011; 365: 1663–1672.
5. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 921–8.
6. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. In: Ryan G (ed) Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 2003. Epub ahead of print July 2003. DOI: 10.1002/14651858.CD001021.
7. Jones AP, Wallis C. Dornase alfa for cystic fibrosis. In: Jones AP (ed) Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 2010. Epub ahead of print March 2010. DOI: 10.1002/14651858.CD001127.pub2.
8. Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. In: Wark P (ed) Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 2009. Epub ahead of print April 2009. DOI: 10.1002/14651858.CD001506.pub3.
9. Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane database Syst Rev 2011; CD001021.
10. Mayer-Hamblett N, Rosenfeld M, Emerson J, et al. Developing Cystic Fibrosis Lung Transplant Referral Criteria Using Predictors of 2-Year Mortality. Am J Respir Crit Care Med 2002; 166: 1550–1555.
11. Quittner AL, Zhang J, Marynchenko M, et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest 2014; 146: 142–151.
12. Nasr SZ, Chou W, Villa KF, et al. Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis. J Med Econ 2013; 16: 801–808.
13. Briesacher BA, Quittner AL, Saiman L, et al. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med 2011; 11: 5.
14. Wertz DA, Chang C-L, Stephenson JJ, et al. Economic impact of tobramycin in patients with cystic fibrosis in a managed care population. J Med Econ 2011; 14: 759–68.
15. Eakin MN, Bilderback A, Boyle MP, et al. Longitudinal association between medication adherence and lung health in people with cystic fibrosis.J Cyst Fibros 2011; 10: 258.
16. Conway D, Peckham T, Daniels L, et al.Electronic Monitoring of Nebulizers Self-Report and Clinician Report vs Accurate Assessment of Adherence. 2011; 140: 425–432.
17. Modi AC, Lim CS, Yu N, et al. A multi-method assessment of treatment adherence for children with cystic fibrosis B,BB. Epub ahead of print 2006. DOI: 10.1016/j.jcf.2006.03.002.
18. Hoo ZH, Curley R, Campbell MJ, et al. Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: Methods to calculate “normative adherence”. Patient Prefer Adherence 2016; 10: 887–900.
19. Hoo ZH, Campbell MJ, Curley R, et al. Do cystic fibrosis centres with the lowest FEV 1 still use the least amount of intravenous antibiotics? A registry-based comparison of intravenous antibiotic use among adult CF centres in the UK. J Cyst Fibros 2017; 1–8.
20. Campbell MJ, Curley R, Wildman MJ. An empirical method to cluster objective nebulizer adherence data among adults with cystic fibrosis. Patient Prefer Adherence 2017; 11: 631–642.
21. Hoo ZH, Boote J, Wildman MJ, et al. Determinants of objective adherence to nebulised medications among adults with cystic fibrosis: an exploratory mixed methods study comparing low and high adherers. Heal Psychol Behav Med 2017; 5: 299–316.
22. Arden MA, Hutchings M, Whelan P, et al. Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: . DOI: 10.1186/s40814-020-00739-2.
23. Michie S, Van Stralen MM, West R. Implementation Science The behaviour change wheel: A new method for characterising and designing behaviour change interventions Michie et al. The behaviour change wheel: A new method for characterising and designing behaviour change interventions. Epub ahead of print 2011. DOI: 10.1186/1748-5908-6-42.
24. Hind D, Drabble SJ, Arden MA, et al. Feasibility study for supporting medication adherence for adults with Cystic Fibrosis: mixed-methods process evaluation. 10. Epub ahead of print 2020. DOI: 10.1136/bmjopen-2020-039089.
25. Ross J, Stevenson F, Lau R, et al. Factors that influence the implementation of e-health: A systematic review of systematic reviews (an update). Implement Sci; 11. Epub ahead of print 2016. DOI: 10.1186/s13012-016-0510-7.
26. Wiltsey Stirman S, Kimberly J, Cook N, et al. The sustainability of new programs and innovations: a review of the empirical literature and recommendations for future research. Implement Sci; 7. Epub ahead of print 2012. DOI: 10.1186/1748-5908-7-17.
27. Michie S, Prestwich A. Are interventions theory-based? Development of a theory coding scheme. Heal Psychol 2010; 29: 1–8.
28. Powell BJ, Beidas RS, Lewis CC, et al. Methods to Improve the Selection and Tailoring of Implementation Strategies. J Behav Heal Serv Res 2015; 177–194.
29. Waltz TJ, Powell BJ, Fernández ME, et al. Choosing implementation strategies to address contextual barriers: diversity in recommendations and future directions.DOI: 10.1186/s13012-019-0892-4.
30. Liang L, Bernhardsson S, Vernooij RWM, et al.Use of theory to plan or evaluate guideline implementation among physicians: a scoping review. Implement Sci 2017; 12: 26.
31. Damschroder LJ. Clarity out of chaos: Use of theory in implementation research. Psychiatry Res. Epub ahead of print June 2019. DOI: 10.1016/j.psychres.2019.06.036.
32. Patey AM, Islam R, Francis JJ, et al.Anesthesiologists’ and surgeons’ perceptions about routine pre-operative testing in low-risk patients: application of the Theoretical Domains Framework (TDF) to identify factors that influence physicians’ decisions to order pre-operative tests. Epub ahead of print 2012. DOI: 10.1186/1748-5908-7-52.
33. Lipworth W, Taylor N, Braithwaite J. Can the theoretical domains framework account for the implementation of clinical quality interventions?, http://www.biomedcentral.com/1472-6963/13/530 (2013, accessed 16 October 2018).
34. Cane J, O’Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci 2012; 7: 37.
35. Michie S, van Stralen MM, West R. The behaviour change wheel: A new method for characterising and designing behaviour change interventions. Implement Sci 2011; 6: 42.
36. Michie S, Atkins L, West R. The Behaviour Change Wheel: A Guide To Designing Interventions. Sutton: Silverback Publishing, 2014.
37. Nilsen P, Roback K, Broström A, et al. Creatures of habit: accounting for the role of habit in implementation research on clinical behaviour change, http://www.implementationscience.com/content/7/1/53 (2012, accessed 26 April 2019).
38. Funnell SC, Rogers PJ. Developing a Theory of Change. In: Funnell SC, Rogers PJ (eds) Purposeful Progam Theory. San Francisco, CA: Jossey-Bass, 2011, pp. 149–240.
39. West R, Michie S. Applying the Behaviour Change Wheel A very brief guide, https://www.ucl.ac.uk/behaviour-change/files/bcw-summary.pdf (accessed 10 November 2017).
40. Grady M. Qualitative and action research: A practitioner handbook. Phi Delta Kappa International, https://books.google.com/books?hl=en&lr=&id=JOr3-A3LbwC&oi=fnd&pg=PA1&dq=Grady+MP.+Qualitative+and+Action+Research:+A+Practitioner+Handbook.
%5D+%5BRef+list%5D&ots=hCSST5jAKZ&sig=fZS4e8aWOtcrEcpPn95ymjx8M38 (1998, accessed 16 November 2020).
41. Bryman A. BRG. Analyzing Qualitative Data. London: Routledge. Epub ahead of print 9 September 1994. DOI: 10.4324/9780203413081.
42. Hind D, Drabble SJ, Arden MA, et al. Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study.DOI: 10.1186/s12890-019-0834-6.
43. Arden MA, Drabble SJ, O’Cathain A, et al.WS16.1 ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework. J Cyst Fibros 2016; 15: S26.
44. Godfrey MM, Oliver BJ. Accelerating the rate of improvement in cystic fibrosis care: Contributions and insights of the learning and leadership collaborative. BMJ Qual Saf 2014; 23 Suppl 1: i23–i32.
45. Marshall M, Pronovost P, Dixon-Woods M. Promotion of improvement as a science. Lancet 2013; 381: 419–421.
46. Dixon-Woods M, Martin GP. Does quality improvement improve quality? Futur Hosp J 2016; 3: 191–194.
47. Braithwaite J, Marks D, Taylor N. Harnessing implementation science to improve care quality and patient safety: a systematic review of targeted literature. Int J Qual Heal Care 2014; 26: 321–329.
48. Groene O, Lombarts MJMH, Klazinga N, et al. Is patient-centredness in European hospitals related to existing quality improvement strategies? Analysis of a cross-sectional survey (MARQuIS study). DOI: 10.1136/qshc.2008.029397.
49. Gardner B, Rebar AL, Gardner B, et al.Habit Formation and Behavior Change. In: Psychology. Oxford University Press. Epub ahead of print 15 January 2019. DOI: 10.1093/obo/9780199828340-0232.
50. Potthoff S, Rasul O, Sniehotta FF, et al. The relationship between habit and healthcare professional behaviour in clinical practice: a systematic review and meta-analysis. Health Psychol Rev 2019; 1–18.
51. Gardner B, Rebar AL, Gardner B, et al. Habit Formation and Behavior Change. In: Psychology. Oxford University Press, 2019. Epub ahead of print January 2019. DOI: 10.1093/obo/9780199828340-0232.
52. Hofmann W, Friese M, Wiers RW. Impulsive versus reflective influences on health behavior: a theoretical framework and empirical review. Health Psychol Rev 2009; 2: 111–137.
53. Carey RN, Connell LE, Johnston M, et al. Behavior Change Techniques and Their Mechanisms of Action: A Synthesis of Links Described in Published Intervention Literature. Ann Behav Med 2018; 1–15.
54. Malterud K, Siersma VD, Guassora AD. Sample Size in Qualitative Interview Studies: Guided by Information Power. Qual Health Res 2015; 1–8.
55. Atkins L, Francis J, Islam R, et al. A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems. Implement Sci 2017; 12: 107–112.
56. Barker PM, Reid A, Schall MW. A framework for scaling up health interventions: lessons from large-scale improvement initiatives in Africa. Implement Sci 2015; 11: 12.
57. Barker PM, Reid A, Schall MW. A framework for scaling up health interventions: lessons from large-scale improvement initiatives in Africa. Epub ahead of print 2016. DOI: 10.1186/s13012-016-0374-x.